Become A Featured Company

FloraWorks Announces Scientific Breakthrough in Natural Sleep Aids: First-Ever Double-Blind, Randomized, Placebo-Controlled Clinical Trial Discovers CBN Effective for Sleep

Ryan Allway

June 28th, 2023

News, Top News, Top Story

Independently Conducted Trial by Radicle Science Finds Florworks’s Flagship TruCBN; Showed a Significant Improvement in Sleep When Compared to Placebo

 

Portland, Oregon–(Newsfile Corp. – June 28, 2023) – A landmark study led by FloraWorks Holdings Inc. (“FloraWorks” or “Company”), a leading cannabinoid therapeutics company, announced the results of the first-ever double-blind, randomized, placebo-controlled trial that analyzed the effects of its flagship product, TruCBN™ – a pure form of Cannabinol (“CBN”) and one of more than 100 known cannabinoids found in the cannabis plant – on sleep.

 

Independently conducted by clinical-research company, Radicle Science, the groundbreaking research compared the effects of TruCBN™ against melatonin and a placebo, among more than 1,000 participants across the U.S. Each participant received one of three different doses: FloraWorks’ TruCBN™, melatonin or a placebo with the trial specifically finding that:

  • The group taking 50 mg of TruCBN™ showed a significant improvement in sleep compared to placebo, and most of the group experienced a clinically important improvement.
  • The group taking 4 mg melatonin also showed a significant improvement in sleep compared to placebo.
  • The group taking 50 mg of TruCBN™ had slightly better sleep improvements compared to 4 mg of melatonin.
  • The groups taking 25 mg and 100 mg of TruCBN™ had marginally significantly better sleep improvements compared to placebo.
  • 50 mg of TruCBN™ delivered better sleep outcomes than 25 mg or 100 mg, which is the first clinical trial data to suggest TruCBN™ may have a U-shaped dose-response curve for sleep.
  • All side effects were mild or moderate. There were no significant differences in the frequency of reported side effects between any dose of TruCBN™ or melatonin compared to placebo.

 

“Our results pave the way for developing more effective sleep solutions, ultimately improving the quality of life for millions of people who struggle with sleep disturbances,” said FloraWorks CEO and Cofounder Alleh Lindquist. “These findings bring needed clarity to the rapidly growing consumer demand for existing CBN products. Our TruCBN™ will be a new competitor in the global sleep aid market and marks a major milestone in building consumer trust and confidence in the therapeutic potential of cannabinoids.“

Radicle Science Cofounder and CEO Jeff Chen, MD/MBA said, “The historical firsts encompassed in this study, especially discovering that CBN may have a U-shaped dose-response curve, have tremendous implications for formulating effective, natural sleep products for Americans. The findings especially highlight the importance of using the right dosage. For CBN, both too much (100 mg) and too little (25 mg) may have decreased effectiveness.”

 

Radicle Science Vice President of Research Affairs Dr. Susan Hewlings, PhD, RD explained, “It’s very promising to discover that CBN could be just as effective – and possibly better – than melatonin, considering many cannot tolerate melatonin’s side effects. This discussion is especially timely given the recent FDA scrutiny towards melatonin dosage and concerns about children consuming melatonin above recommended doses.”

 

Clinical findings like these from FloraWorks and Radicle Science have the potential to become major market disruptors to the legacy over-the-counter sleep aid market. Sixty percent (60%) of Americans report they get less than the recommended seven hours of sleep per night and poor sleep has become a public health concern as it is linked to many health issues, including inflammatory conditions, obesity, heart disease and overall reduced quality of life. As consumers increasingly seek natural and safe alternatives for better sleep, the introduction of a non-intoxicating hemp-derived cannabinoid solution presents an attractive option. TruCBN™ could lead to a decline in demand for traditional sleep aids as the results of this study build consumer trust and confidence in TruCBN™ as a natural alternative sleep aid.

 

About FloraWorks:

FloraWorks is a leading cannabinoid therapeutic development company specializing in high-quality, innovative products designed to improve health and wellness. With a focus on safety, efficacy and consumer trust, FloraWorks is dedicated to unlocking the therapeutic potential of rare and novel cannabinoids, and creating effective solutions that cater to a wide range of needs. For more information, visit www.flora-works.com.

 

 

About Radicle Science:

Radicle Science is history’s first Proof-as-a-Service company, enabling non-prescription health and wellness products to clinically prove their true effects beyond placebo. They offer non-pharmaceutical products the first easy path to generate first-of-its-kind clinical evidence across diverse conditions and populations at unprecedented affordability, speed, and scale. Radicle’s transformative approach democratizes access to clinical trials and can finally close the “proof gap” between non-prescription wellness products and pharmaceutical drugs.

 

For media inquiries, please contact:

Ellen Mellody
570-209-2947
floraworks@mattio.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading